Gilead is no stranger to sponsoring and conducting trials in Australia.
Whether for commercial reasons or for the scientific prowess/community I have no idea BUT there is NO DOUBT their contact network here is already in place, hospitals included.
So may be AB's and thrasher's joining the dots isn't too far off the mark.
Take a look at the below stats and ponder the possibilites!
"In early phase clinicaltrials Australia is28 per cent cheaperthan the US beforetax incentives, and60 per cent cheaperafter tax incentives." Quote from: Australia: Preferred Destination forEarly Phase Clinical Trials. Frost &Sullivan White Paper 2016
SPL Price at posting:
$1.09 Sentiment: Hold Disclosure: Held
